MAA submitted to the European Medicines Agency for approval of single tablet combination therapy of macitentan and tadalafil for treatment of pulmonary arterial hypertension – Jansen Pharmaceuticals

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of a single tablet combination therapy of macitentan 10 mg and tadalafil 40 mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients of […]